Try our beta test site
15 studies found for:    Open Studies | CLL OR SLL | Phase 3
Show Display Options
Rank Status Study
1 Recruiting A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab
2 Recruiting Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Bendamustine;   Drug: Venetoclax;   Biological: Obinutuzumab;   Drug: Ibrutinib
3 Recruiting A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Venetoclax
4 Recruiting A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Venetoclax
5 Recruiting A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ACP-196;   Drug: Rituximab;   Drug: Idelalisib;   Drug: Bendamustine
6 Recruiting Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Drug: Placebo
7 Recruiting Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ACP-196;   Drug: ibrutinib
8 Recruiting A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
Condition: Chronic Lymphocytic Leukaemia
Interventions: Drug: Ofatumumab;   Drug: Chlorambucil;   Drug: Bendamustine
9 Recruiting Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: Obinutuzumab;   Biological: Ublituximab;   Drug: TGR-1202;   Drug: Chlorambucil
10 Not yet recruiting Combination of Ibrutinib and As2O3 in the Treatment of CLL
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: Ibrutinib combined with As2O3;   Drug: ibrutinib
11 Recruiting Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Conditions: Chronic Lymphocytic Leukemia;   Indolent B-cell Lymphomas;   Chronic Hepatitis B;   Lymphoma, Small Lymphocytic;   Mantle-Cell Lymphoma;   Waldenstrom's Macroglobulinaemia;   Follicular Lymphoma
Intervention: Drug: Ibrutinib
12 Not yet recruiting A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma;   Mucosal-Associated Lymphoid Tissue Lymphoma
Interventions: Dietary Supplement: Vitamin D;   Biological: rituximab;   Other: Placebo
13 Recruiting Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Conditions: B-cell Non Hodgkin Lymphoma;   Mature B-cell Leukemia Burkitt-type
Interventions: Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;   Drug: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
14 Recruiting Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Conditions: Follicular Lymphomas;   Immunocytomas;   Marginal Zone Lymphomas;   Mantle-Cell Lymphomas;   Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Rituximab / observation
15 Recruiting Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
Interventions: Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)

Study has passed its completion date and status has not been verified in more than two years.